Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
Rachael A. Evans, Sabada Dube, Yi Lu, et al.
The Lancet Regional Health - Europe (2023) Vol. 35, pp. 100747-100747
Open Access | Times Cited: 114

Showing 1-25 of 114 citing articles:

Disparities in COVID-19 mortality amongst the immunosuppressed: A systematic review and meta-analysis for enhanced disease surveillance
Meredith Leston, Willam Elson, José M. Ordóñez‐Mena, et al.
Journal of Infection (2024) Vol. 88, Iss. 3, pp. 106110-106110
Open Access | Times Cited: 19
Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study
Jennifer K Quint, Sabada Dube, Lucy Carty, et al.
Journal of Infection (2025) Vol. 90, Iss. 3, pp. 106432-106432
Open Access | Times Cited: 2
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
Ghady Haidar, S. Thomas, Paul Loubet, et al.
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 2
In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms
S. Cankat, M. U. Demael, Leo Swadling
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 103-118
Open Access | Times Cited: 34
B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience
Alessandra D’Abramo, Serena Vita, Alessia Beccacece, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 13
Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US Study
Amita Ketkar, Vincent J. Willey, Lisa Glasser, et al.
Advances in Therapy (2024) Vol. 41, Iss. 3, pp. 1075-1102
Open Access | Times Cited: 11
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 10
AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults
Yíngyún Caì, Seme Diallo, Kim Rosenthal, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 753
Closed Access | Times Cited: 10
A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification
Laura E. Rosen, M. Alejandra Tortorici, Anna De Marco, et al.
Cell (2024)
Open Access | Times Cited: 10
Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study
Lisa Mumford, Rachel Hogg, Adam Taylor, et al.
The Lancet (2025) Vol. 405, Iss. 10475, pp. 314-328
Open Access | Times Cited: 1
Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023–2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach
Ryan E. Wiegand, Owen Devine, Megan J. Wallace, et al.
Vaccine (2025) Vol. 49, pp. 126808-126808
Closed Access | Times Cited: 1
Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review
Manuela H Gschwend, Anthony M. Marchese, Dirk Poelaert, et al.
Vaccine (2025) Vol. 49, pp. 126777-126777
Open Access | Times Cited: 1
Clinical Outcomes of Hospitalized Immunocompromised Patients With COVID-19 and the Impact of Hyperinflammation: A Retrospective Cohort Study
Xinxin Zhang, Han Xiao-bo, Chenglong Li, et al.
Journal of Inflammation Research (2025) Vol. Volume 18, pp. 3385-3397
Open Access | Times Cited: 1
Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study
Lance Turtle, Sarah Elliot, Thomas M Drake, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 5, pp. 636-648
Open Access | Times Cited: 8
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity
Raymund R. Razonable
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
The prevalence, determinants, and consequences of post‐COVID in healthcare workers: A cross‐sectional survey
Anastasia Saade, Quentin Didier, Léo Cha, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 6
Closed Access | Times Cited: 5
Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis
Maria Mazzitelli, Alberto Enrico Maraolo, Claudia Cozzolino, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 5
Hybrid Immunity Improves the Immune Response after the Fourth COVID-19 Vaccine Dose in Individuals with Medical Conditions Predisposing to Severe COVID-19
Nina Ekström, Tuija M. Leino, Aapo Juutinen, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 247-247
Open Access | Times Cited: 4
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19
Lindsay E. Clegg, Oleg Stepanov, Henning Schmidt, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 5
Open Access | Times Cited: 4
Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019
Chie Yamamoto, Masashi Taniguchi, Keitaro Furukawa, et al.
Viruses (2024) Vol. 16, Iss. 5, pp. 718-718
Open Access | Times Cited: 4
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease
Simon Woelfel, Joel Dütschler, Daniel Junker, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 774-774
Open Access | Times Cited: 4
SARS-CoV-2 Variants and Clinical Outcomes of Special Populations: A Scoping Review of the Literature
Achilleas Livieratos, Charalambos Gogos, Karolina Akinosoglou
Viruses (2024) Vol. 16, Iss. 8, pp. 1222-1222
Open Access | Times Cited: 4
Humoral responses to SARS-CoV-2 vaccine in vasculitis-related immune suppression
Kimia Kamelian, Benjamín L. Sievers, Michael Chen‐Xu, et al.
Science Advances (2025) Vol. 11, Iss. 7
Open Access
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics
Giulia Dowgier, Agnieszka Hobbs, David Greenwood, et al.
Vaccine (2025) Vol. 54, pp. 126960-126960
Closed Access
The Impact of the COVID-19 Omicron Variant on Immunocompromised Patients: ICU Admissions and Increased Mortality
Jan Pander, Fabian Termorshuizen, Dylan W. de Lange, et al.
Infectious Diseases and Therapy (2025)
Open Access
Page 1 - Next Page

Scroll to top